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Orphan drugsRare diseases are those with a particularly low prevalence; in Europe, diseases are considered to be rare when
they affect not more than 5 in 10 000 persons in the European Union. The speciﬁcities of rare diseases make
the area a veritable public health challenge: the limited number of patients and scarcity of knowledge and
expertise single rare diseases out as a distinctive domain of high European added-value. The Orphan Medicinal
Product Regulation of 1999 was the ﬁrst European legislative text concerning rare diseases, followed by many
initiatives, including recommendations by the Council of Ministers of the European Union in 2009. These
initiatives contributed to the development of rare diseases policies at European and national level aimed at
improving care for patients with rare diseases. A review of the political framework at European level and in
European countries is provided to demonstrate how legislation has created a dynamic that is progressively
improving care for patients with rare diseases. This article is part of a Special Issue entitled: “Current Research
on the Neuronal Ceroid Lipofuscinoses (Batten Disease)”.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rare diseases are those with a particularly low prevalence. The
threshold to deﬁne rarity differs across countries and regions; the
European Union considers diseases to be rare when they affect not
more than 5 in 10 000 persons in the European Union. This deﬁnition
ﬁrst appeared in the 1999 Regulation (EC) 141/2000 on Orphan Medic-
inal Products [1], and it is estimated that around 7000 rare diseases exist
[2]. The Orphan Medicinal Product Regulation of 1999 was the ﬁrst
European legislative text concerning rare diseases and represented the
start of a commitment at European level to the development of rare
diseases policies at European level aimed at improving care of patients
with rare diseases. The speciﬁcities of rare diseases make the area a
veritable public health challenge: the limited number of patients and
scarcity of relevant knowledge and expertise single rare diseases out
as a distinctive domain of high European added-value [3]. European
cooperation can help ensure that scarce knowledge is shared and
resources are combined as efﬁciently as possible, in order to tackle
rare diseases across the European Union as a whole. This paper will
provide a review of the political framework at European level and
in European countries to demonstrate how legislation has created a
dynamic that is progressively improving care for patients with a rareesearch on theNeuronal Ceroid
Rare Diseases Platform, 96 rue
ell).
. This is an open access article underdisease in areas as diverse as organisation of healthcare, diagnostics,
research, therapies, information services and patient support.
2. Materials and methods
A review of the state of the art of rare disease policy and activities at
National, European and International levels was conducted, based on
the work carried out by the European Union Committee of Experts
(EUCERD) Joint Action Scientiﬁc Secretariat in order to produce the an-
nual “Report on the State of theArt of Rare Diseases Activities in Europe”
[4], in particular theﬁrst volumeof the 2014 edition of this reportwhich
provides an overview of the state of play and initiatives in the ﬁeld. The
main legislative texts in the ﬁeld of rare diseases at national, European
and International level were also examined. The survey also took into
consideration the information published by the newsletter of the rare
disease community, OrphaNews [5], in addition to the sources of the
“Report on the State of the Art of Rare Diseases Activities in Europe” as
cited in its bibliography.
The impact of European and national rare disease related policies on
the various sectors of activities at play within the ﬁeld of rare diseases is
presented in the results.
3. Results
3.1. Political framework
Political concepts and initiatives in Europe concerning rare diseases
progressively emerged at the end of the 20th century at both European
Union (EU) and Member State (MS) level, paving the way for thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the ﬁeld. Sweden, for example, established the ﬁrst centres of expertise
for rare diseases in 1990 and a rare disease database and information
centre in 1999; Denmark established an information centre in 1990
and centres of expertise for rare diseases in 2001; in France, the rare dis-
ease and orphan drug database Orphanet was established in 1997 with
the support of the French Ministry of Health and the INSERM (French
National Institute for Health and Medical Research), followed by a na-
tional plan for rare diseases in 2004 which was the ﬁrst of its kind in
the world. Around the same time, a number of other countries in
Europe (Bulgaria, Greece, Portugal and Spain) were elaborating a na-
tional plan or strategy for rare diseases, whilst the EU policy in the
ﬁeld was deﬁned through the European Commission (EC) Communica-
tion on Rare Diseases (2008) [3], and the Council Recommendation on
an action in the ﬁeld of rare diseases (2009) [6], building on the previ-
ously mentioned 1999 Regulation on Orphan Medicinal Products.
Today, policy at national level is generating momentum in the wake of
EU policy in response to the Council Recommendation's call for
countries to adopt a national plan or strategy aimed at guiding and
structuring actions in the ﬁeld of rare diseases within the framework
of their health and social systems. Twenty of the twenty-eight countries
in the EU have adopted such a plan or strategy to date and the others are
in the process of adopting their plan or strategy (Fig. 1).
3.1.1. European level
Four key policy documents have established the political framework
for action in the ﬁeld of rare diseases and orphan medicinal products at
European level. Firstly in 1999, the Orphan Medicinal Product Regula-
tion N° 141/2000 [1] of the European Parliament and the Council on or-
phanmedicinal products established the criteria for orphan designation
in the EU and described the proposed incentives to encourage the re-
search, development andmarketing ofmedicines to treat, prevent or di-
agnose rare diseases. This Regulation also established the European
deﬁnition of a rare disease as a disease with a prevalence of not moreFig. 1. Evolution of rare disease policythan 5 per 10 000 persons in the European Union. Fifteen years after
its adoption, the Regulation can be seen as a success (see 3.5) with
over 80 orphan medicinal products having received market authorisa-
tion to date.
This Regulation provided the basis for the development of an overall
EU strategy to support countries in the diagnosis, treatment and care of
their citizens with a rare disease. In 2008, the EC published a report on
Rare Diseases [3], entitled Rare Diseases: Europe's Challenge, which
recognised the potential for maximising the scope for cooperation and
mutual support in this singular area across Europe as a whole. It
highlighted the need to improve the recognition and visibility of rare
diseases, to support policies on rare diseases inMS for a coherent overall
strategy, and to develop cooperation, coordination and regulation for
rare diseases at EU level. Based on this report and the wide-ranging ob-
jectives it set for the European community, the European Council of
health ministers adopted in 2009 a Recommendation on an action in
the ﬁeld of rare diseases [6]. Engaging the responsibility of European
countries, the Recommendation encourages the elaboration and adop-
tion of national plans and strategies for rare diseases by the end of
2013. Countries were encouraged to consider in these plans/strategies
aspects such as the improvement of the recognition and visibility of
rare diseases, encouragement of research into rare diseases, the devel-
opment of links between experts and centres of expertise in different
countries to identify and pool expertise at European level, the empow-
erment of patient organisations, and the development of sustainability
in the ﬁeld of information, research and healthcare infrastructures.
To help the EC in the implementation of the objectives of the Com-
mission Communication and Council Recommendation, the European
Committee of Experts on Rare Diseases [7] (EUCERD) was established
in 2009. The EUCERD followed in the footsteps of the EC's Rare Diseases
Task Force which was the ﬁrst committee of its type at European level,
meeting from 2004 to 2009. The EUCERD was a multi-stakeholder
forum that succeeded in adopting, during its 3 year mandate, 5 sets of
recommendations aimed at guiding the EU and Member States in thein Europe (December 2014) [4].
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Committee was replaced by the EC Expert Group on Rare Diseases
(EGRD) [8] which continues to aid the EC in shaping their rare disease
policies.
European ﬁnancing was also provided to a number of projects to
support the EU policy in the ﬁeld in the framework of the Second
Programme of Community Action in the Field of Public Health [9].
The Commission published in 2014 a report [10] that considered the
extent to which the proposed measures of the Commission Communi-
cation and Council Recommendation are working effectively to make
improvements in the ﬁeld. The report takes stock of the successes to
date, and outlines the EU's intention to maintain a coordinative role
in the development of the EU policy on rare diseases and to support
Member States in their national activities in this ﬁeld.
Rare diseases were also speciﬁcally addressed in Directive 2011/24/
EU on the application of patients' rights in the cross-border healthcare
[11], approved in 2011. This Directive seeks to facilitate access to health
care for EU citizens and encourage cooperation between EU MS in the
ﬁeld of health, of particular interest in the ﬁeld of rare diseases where
patients and expertise are rare and scattered across the EU. In particular,
the Directive encourages the establishment of European Reference
Networks in the ﬁeld of rare diseases to pool expertise and improve
care for patients.3.1.2. National level
At national level in Europe, the state of play as regards the develop-
ment of national rare disease policies, plans and strategies differs greatly
from country to country:whereas France is reaching the end of a second
National Plan for Rare Diseases, some countries are still in the process of
bringing together stakeholders to determine where action is needed.
The Council Recommendation [6] has served as a catalyst in the devel-
opment of national plans and strategies for rare diseases in EU countries.
Whereas only 5 countries had developed such a plan or strategy at the
time of its adoption in 2009, by the end of 2013 (the date by which
the Council Recommendation encouraged countries to adopt a plan)
16 countries had adopted a plan/strategy with the others in advanced
stages of the elaboration of a plan/strategy. Four additional countries
adopted a plan/strategy by the end of 2014, bringing the total to 20
out of the 28 European Union Member States (Table 1).
These plans/strategies vary in their scope and their ﬁnancing which
will ultimately inﬂuence the extent of their impact at national level.
Some countries have still to deﬁne the elements outlined in their poli-
cies in speciﬁc work plans. The main issues of concern tackled by
these policies are: the organisation of expert care for rare diseases with-
in the existing healthcare system, the adequate coding of rare diseases
within health information systems, the registration of patients with
rare diseases at national level, and the provision of information on
rare diseases through support to the European rare disease and orphan
drug database, Orphanet [12].
It should be noted that the current economic context is having a
negative impact on the development and implementation of these
plans: many plans may have insufﬁcient or no funding as a result, thus
potentially limiting their impact.Table 1
State of evolution of national plans/strategies in European Union Member States in
December 2014 [4].
• National plans/strategies fully implemented: France, Spain
• National plans/strategies adopted: Belgium, Bulgaria, Cyprus, Czech Republic,
Denmark, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Portugal,
Romania, Slovak Republic, Slovenia, the Netherlands, and United Kingdom.
• National plan/strategy submitted to national authorities: Austria, Croatia, Estonia,
Finland, Malta, Poland, and Sweden.
• Drafting group/stakeholder meetings being held: Luxembourg3.1.3. Other world regions
Outside of the European region, a number of countries have devel-
oped political frameworks in the ﬁeld of rare diseases. Mostly, these ini-
tiatives concern the regulation of orphan medicinal products. Policies
for orphan medicinal products started as early as 1983 in the United
States with the adoption of the Orphan Drug Act, then in Japan (1993)
and in Australia (1997). Europe followed suit in 1999 by implementing
a common EU policy on orphan medicinal products [1]. The European
Council Recommendation on an action in the ﬁeld of rare diseases [6]
and the elaboration of national plans/strategies in European countries
is inspiring other countries around the world to consider the necessity
of a national policy for rare diseases and efforts are being made in a
number of countries to explore possibilities in this area [4].3.2. Centres of expertise and European Reference Networks
3.2.1. Centres of expertise for rare diseases
The identiﬁcation, and creation, of centres of expertise for rare dis-
ease is a key element of the Council Recommendation and central to na-
tional rare disease plans/strategies. With around 7000 rare diseases
identiﬁed to date, the majority unknown to healthcare professionals,
rare disease patients suffer fromnot knowingwhere to consult. To over-
come this, some EU countries have established centres specialised in
some rare diseases/groups of rare diseases which have proven to be
very efﬁcient in improving the quality of care for rare disease patients.
The networking of these centres could lead to the gathering of the scarce
expertise concerning these diseases at European level, in order to
ensure equal access to accurate information, appropriate and timely
diagnosis and high quality care for rare disease patients.
Currently, the organisation of centres of expertise varies greatly from
country to country in Europe: few countries currently have a designa-
tion process in place and the designation criteria vary from country to
country, and sometimes even from region to region within a country
(Table 2).
In order to provide guidance to countries wishing to elaborate simi-
lar processes within the scope of their national plans/strategies for rare
diseases, the EUCERD established a set of Recommendations on Quality
Criteria for Centres of Expertise for Rare Diseases in Member States in
2011 [13].
These recommendations outline the mission and scope of such
centres, the general quality criteria to be considered in a designation
process, guidance concerning the evaluation procedures for centres of
expertise, and the European dimension of these centres in terms of
their future implication in the European Reference Networks (ERNs)
to be created within the scope of the Directive on the application of pa-
tients' rights in cross-border healthcare. These ERNs are supposed to be
networks, at European level, between national centres of expertise.
Many countries are currently using and/or adapting these recom-
mendations to their national context, mostly within their national
plans/strategies: this action will both provide better care for patients
at national level, and also to prepare for the implementation of
European Reference Networks. As a result, the designation criteria
adopted should be relatively homogenous from country to countryTable 2
State of the art of centres of expertise at national level in European Member States in
December 2013 [4].
• Centres of expertise designated in the context of a national rare disease
plan/strategy: France
• Centres of expertise designated outside of a national RD plan/strategy: Denmark,
Italy (regional), Spain, Sweden, and United Kingdom.
• Countries with plans to designate centres of expertise within a national rare
disease plan/strategy: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech
Republic, Finland, Greece, Germany, Hungary, Ireland, Latvia, Lithuania, Poland,
Portugal, Romania, the Netherlands, Slovenia, and Slovak Republic.
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and the creation of European Reference Networks.
3.2.2. European Reference Networks for rare diseases
As a means of organising care for the thousands of heterogeneous
rare conditions affecting scattered patient populations across Europe,
the creation of European Reference Networks (ERNs) is foreseen by
the Council Recommendation on an Action in the Field of Rare Diseases
and more recently in the Directive on the application of patients' rights
in cross-border healthcare. ERNs, as networks of highly specialised
healthcare providers from different MS, are of particular relevance to
the ﬁeld of rare diseases. These structures will aim to improve knowl-
edge on rare diseases, facilitate the mobility of expertise, and allow
Member States to provide highly specialised services of high quality
for patients where this would have been impossible without European
networking.
The European legislative texts listing the criteria and conditions that
healthcare providers and the ERNs should fulﬁl, as well as containing
criteria for establishing and evaluating ERNs have been adopted in
2014 [14] and are in line with the recommendations of the EUCERD in
the ﬁeld, issued in 2013, concerning the speciﬁcities of ERNs for rare
diseases [15].
The EC is currently in the process of deﬁning the designation, assess-
ment and evaluation processes prior to launching theﬁrst calls for ERNs.
The rare disease community hopes that, over time, all RD will be repre-
sented by ERNs in a step-wise manner: a discussion is currently under-
way at the Commission Expert Group on Rare Diseases concerning the
best grouping of diseases as only a limited number of ERNs will be
designated. Due to the complexity of rare diseases, these networks
should link centres of expertise as well as other stakeholders involved
in the care management of the patients such as specialised health and
social care providers, patient groups, research groups and diagnostic
laboratories.
Currently, a number of non-designated networks exist in the ﬁeld of
rare diseases at European level, of which the experiences have fed into
the reﬂection process at European level, including the EUCERD Recom-
mendations on ERNs for rare diseases. These networks, some of which
have received European ﬁnancing, are mostly based on collaborations
between personal experts and their activities are extremely heteroge-
neous, varying greatly depending on the disease/group of diseases
covered [16].
3.3. Adequate identiﬁcation and coding of rare diseases
The International Classiﬁcation of Diseases (ICD) is used worldwide
and by a range of stakeholders, in particular for coding activities within
healthcare systems. Most rare diseases are absent from ICD10, the cur-
rent version of the classiﬁcation, and those with a speciﬁc code are
often misclassiﬁed. As a result, morbidity and mortality due to rare dis-
eases are invisible in health information systems. Improved codiﬁcation
for rare diseases is cited as a priority in the Council Recommendation on
an action in the ﬁeld of rare diseases. Having codes for each rare disease
would help health authorities obtain a better knowledge of healthcare
pathways and of their impact on specialised health care services as
well as on a budget planning for health and social services.
To ensure thatmost rare diseaseswill have a code in the next edition
of ICD (ICD11), expected in 2017, the EC has supported the ICD revision
process.1 In the current beta version [17] of ICD11, over 5000 rare dis-
eases are listed. Although great efforts have been made to integrate
rare diseases into the next version of ICD, a solution is needed to ensure
that rare diseases are coded adequately as soon as possible, as the im-
plementation of ICD11 may not happen immediately after adoption by
the World Health Assembly.1 Through two consecutive Joint Actions (No 2008 22 91 and No 2011 22 11).Orphanet [12], the rare disease and orphan drug database, gives free
access to a nomenclature of rare diseases, fully aligned with ICD10, ICD
11 (beta version) and other nomenclatures (SNOMED-CT, MeSH, HPO,
MedDRA and OMIM). The EGRD proposes in its recommendations on
ways to improve codiﬁcation for rare diseases [18], that countries con-
sider the use of Orphacodes to complement existing coding systems
when no speciﬁc code exists for a rare disease. This approach is current-
ly being piloted in France and Germany. As Orphacodes are alignedwith
the next version of ICD, when ICD11 is implemented, the transition to
the new system will be seamless. A working party of the majority of
Member States who have expressed their interest in this approach is
also being created in order to share experiences concerning the imple-
mentation of Orphacodes in health information systems. A master ﬁle
aligning Orphacodes and all ICD national extensions is foreseen to
ease the process.
In addition to the promotion of Orphacodes, another initiative is
gathering speed: the International Consortium for Human Phenotype
Terminologies (ICHPT)was launched in 2012, bringing together the dif-
ferent terminologies in the ﬁeld of rare diseases, with the aim to decide
upon a set of core terms representing main phenotypic anomalies en-
countered in the ﬁeld of rare diseases to be published and recommend-
ed for use. ICHPT will provide a mapping between the core set of terms
in HPO, PhenoDB, Orphanet, Elements of Morphology, POSSUM,
SNOMED, MeSH, and MeDRA. These terms are also recommended for
inclusion in ICD11 and SNOMED. This initiativewill hopefully effectively
harmonise data and improve the interoperability of databases and thus
accelerate research in the near future.3.4. Research and development
There is a great need for research and development in the ﬁeld of
rare diseases as, so far, most patients' medical needs are not being
met. The rare disease ﬁeld is considered to be an area which requires
speciﬁc initiatives to attract academic and industrial interest. In addi-
tion, experts are very rare. Rarity has an impact on research and R&D,
in the form of a number of bottlenecks: a lack of necessary collaborative
efforts, limited access to platforms, the need for alternative clinical trial
designs, and a limited number of patients for clinical research, aswell as
the challenge accompanying the use of innovative approaches.
The ﬁeld of rare diseases, however, presents many opportunities to
drive forward research and R&D in general: for example, rare diseases
were instrumental in mapping the human genome and in cloning
genes, as most rare diseases are Mendelian disorders. There is a high
level of interest in the biomedical research community to dissect genetic
mechanism, which translates into an improvement in testing possibili-
ties for many rare diseases and a better understanding of common dis-
ease mechanisms. However, the natural history of rare diseases, in
contrast, is often poorly understood due to the obstacle presented by
the inability to collect sufﬁcient data for studies due to the rarity of
these diseases. A lack of interest in this stage in research is compounded
by the current difﬁculty in using medical records in health information
systems due to the inadequate codiﬁcation of rare diseases in ICD10.
Systematic data collection only takes place for a few rare diseases,
which presents an obstacle to the development of therapies and good
practice guidelines.
As previouslymentioned, the ﬁeld of rare diseases can drive forward
research and R&D in general as rare diseases are models for common
diseases: as most rare diseases result from a dysfunction of a single
pathway due to a defective gene, understanding the impact of this de-
fect yields insights into complex pathways in, generally, multifactorial
common diseases. Therefore, promotion of rare disease research is ben-
eﬁcial for the wider scientiﬁc community. This interest has translated
into the involvement of the pharmaceutical and biotechnology industry
in developing new treatments for unmet needs: both innovative and
classical approaches can be efﬁcient in treating rare diseases.
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Research in the ﬁeld of rare diseases is one of the priorities of the
Council Recommendation: it encourages European countries to work
at national and community levels to include provisions aimed at foster-
ing research in their national plans/strategies for rare diseases, to iden-
tify needs in all areas of rare diseases research, and to foster the
development of and participation in cooperative research projects on
rare diseases at European level.
At national level, very few European countries currently have specif-
ic funding programmes for research in the ﬁeld of rare diseases, al-
though some speciﬁc calls are often funded through funds raised by
charities and patient organisations. The national rare disease research
carried out inmost European countries comes from the general research
funding programmes.
At European level, The ECDirectorate General for Research and Inno-
vation has included rare diseases as a priority area since the 1990swith-
in the EU research programmes [19]. From 2007 to 2013, around 120
research projects related to rare diseases were ﬁnanced in the health
theme, with an EU contribution of €620 million [4]. The Orphanet data-
base contains around 5700 ongoing research projects for around 2100
rare diseases taking place in EU and surrounding countries participating
in the Orphanet consortium [4].
One of the funded initiatives is the ERA-Net for rare diseases re-
search entitled, E-Rare [20]. This consortium of research-funding bodies
in 13 European and associated countries (plus 2 observer countries) has
launched annual joint transnational calls since 2007 for collaborative
and multidisciplinary research projects. The initiative has proved to be
a success, with a high rate of proposals received each year in relation
to the available funding.
In Horizon 2020 [19], the Framework Programme running from
2014 to 2020, the EC has renewed its engagement in theﬁeld of rare dis-
eases, with funding earmarked for the continuation of E-Rare's activities
and projects aimed at new therapies of rare diseases. Through its new
research programme, the EC will support the objectives of the Interna-
tional Rare Disease Research Consortium (IRDiRC) [21] established in
2011 at the initiative of the Commission and the US National Institutes
of Health. This consortium of around 40 funding bodies and organisa-
tions from Europe, North America, theMiddle-East, Asia and Australasia
and researchers aims to achieve the objective of 200 new therapies and
diagnostic tools for most rare diseases by 2020.
3.4.2. Disease registries
Patient registries are a key aspect of national plans/strategies for rare
diseases and are cited as a crucial source of information on rare diseases,
in terms of basic and clinical research as well for epidemiological and
public health purposes, to be supported at national and European levels
in the Council Recommendation. Patient registries are a key tool for
gathering the scarce knowledge relevant to rare diseases so as to im-
prove the understanding of these conditions and the treatment avail-
able to patients, as well as the planning of healthcare services for
these diseases. In January 2014 therewere around 640 disease registries
in Europe registered in the Orphanet database, of which 40 were
European (many of which have been supported by EU ﬁnancing), 74
were international, 446 were national, and 77 were regional [22]).
At the national level many countries are considering in the scope of
their national plans/strategies the best way to collect data relative to
rare disease patients, and at the Community level the EC is in the pro-
cess of establishing a European Platform for Rare Disease Registration.
The EUCERD adopted a set of Recommendations on Rare Disease Patient
Registration and Data Collection [23] in 2013 with the aim of setting
down the consensus reached to date and to guide all stakeholders at
this crucial moment in the collective reﬂection on the topic. These rec-
ommendations are also feeding into discussions on data collection and
registration underway at international level in the working groups of
the IRDiRC, notably concerning interoperability and pooling of data for
research purposes.3.5. Therapies for rare diseases
The EU Regulation on Orphan Medicinal Products adopted in 1999
was the ﬁrst European policy text in the ﬁeld of rare diseases. The Reg-
ulation addresses the need to offer incentives for the development and
marketing of drugs to treat, prevent or diagnose rare diseases; without
such incentives, it is unlikely that products would be developed for
these diseases as the cost of development and marketing would not
be recovered by sales. The incentives proposed by the legislation aim
to assist sponsors receiving orphan medicinal product designations in
the development of medicinal products with the ultimate goal of pro-
viding medicinal products for rare diseases to patients. The designation
is granted if themedicinal product is intended for the diagnosis, preven-
tion or treatment of a life-threatening or chronically debilitating condi-
tion affecting not more than 5 in 10 000 persons in the EU when the
application is made, and that there exists no satisfactory method of di-
agnosis, prevention or treatment of the condition in question that has
been authorised in the EU, or if such method exists, that the product
will be of signiﬁcant beneﬁt to those affected by that condition. The
Committee for Orphan Medicinal Products (COMP) at the European
Medicines Agency (EMA) provides opinions on designation applications
which are then adopted by the EC.
At the end of 2013, more than 1234 positive opinions for orphan
product designations had been adopted by the COMP from the 1798 ap-
plications received since 2000 [24]. Eighty-ﬁve orphan designated prod-
ucts had received market authorisation by the end of 2013 [24]. The
incentives provided by the Regulation have thus resulted in the devel-
opment and marketing of medicinal products for rare diseases which
would perhaps not have been so without such an initiative.
However, although these products are technically available in all
European countries as they have been accorded EU market authorisa-
tion by the EC, they may not be accessible. The accessibility of orphan
medicinal products varies from product to product and from country
to country, depending on the price of the product and whether or not
the product has been launched on themarket in a particular country. In-
deed, one of the main factors limiting access to new orphan medicinal
products in the EU is no longer market authorisation, but Health Tech-
nology Assessment (HTA). Two initiatives have been taken in this ﬁeld
at European level which aim, ultimately, to improve access to Orphan
Medicinal Products. The ﬁrst is a set of recommendations issued by
the EUCERD on improving informed decisions based on the clinical
added value of orphan medicinal products information ﬂow (2012)
[25]: this informationﬂowwould consist in earlier dialogue between in-
terested parties including HTA agencies for them to communicate very
early on in the process the data requirements necessary for an assess-
ment of the clinical added value of a given drug to be made. The second
initiative is the pilot projects supported by the EC to develop a mecha-
nism of coordinated access to orphan medicinal products (2013) [26].
3.6. Patient organisations
The key role played by patient organisations in the empowerment of
patients with rare diseases and the necessity of patient involvement in
the rare disease ﬁeld is underlined by the Council Recommendation. At
the end of 2013, around 2500 disease-speciﬁc patient organisations
were registered in theOrphanet database [4]. National alliances of patient
organisations have been established in most European countries to pro-
vide patients with a common voice and the presence necessary to have
an impact on national policy, notably in the development of national
plans/strategies for rare diseases. The Member States where National Al-
liances have been established include: Austria, Belgium, Bulgaria, Croatia,
Cyprus, Czech Republic, Denmark, Finland, France, Germany, Greece,
Hungary, Ireland, Italy, Luxembourg, the Netherlands, Poland, Portugal,
Romania, Slovak Republic, Spain, Sweden and the United Kingdom.
At European level, Eurordis [27], the non-governmental alliance of
patient organisations and individuals active in the ﬁeld of rare diseases,
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EURORDIS is a key actor in the rare disease ﬁeld and its representatives
are actively involved in the rare disease activities of the EC and the
EuropeanMedicines Agency. EURORDIS runs the Council of National Al-
liances of Rare Disease Patient Alliances, which brings together national
representatives of rare diseases to work together on common European
and international actions.
EURORDIS also initiated in 2008 the annual Rare Disease Day, which
takes place on the last day of February. This event aims to raise aware-
ness of patients, families and carers living with rare diseases through
events organised at national level by rare disease patient alliances, and
coordinated at international level by EURORDIS. The day has been
adopted across Europe and across the globe, giving momentum to rare
disease policy and advocacy.
3.7. Information services
A number of initiatives have been taken to improve the availabil-
ity of information concerning rare diseases for professionals, pa-
tients, and policy makers alike. Due to the rarity of these diseases,
the scarce knowledge concerning many rare diseases, and the rare
and scattered expertise in this ﬁeld, a European-level, concerted ap-
proach is essential.
At European level, Orphanet, the rare diseases and orphan drug
database, is supported by the EC with the support of Member States.
In addition, there are two European initiatives to improve communi-
cation about rare diseases and activities in the ﬁeld: a dedicated
newsletter, OrphaNews [5], and a State of the Art of Rare Diseases
report [29], providing a comprehensive overview of rare diseases ac-
tivities at European and Member State level. At Member State level,
Orphanet national teams collect information concerning expert ser-
vices in their country for inclusion in Orphanet [12], and some coun-
tries have additional rare disease information centres and/or
helplines where patients and professionals can seek information
and advice concerning rare diseases.
3.7.1. Orphanet
Orphanet [12] is the reference portal for information on rare diseases
and orphan drugs in Europe. Established in 1997 by the FrenchMinistry
of Health and the INSERM (French Institute of Health and Medical Re-
search), the database and web portal have been supported by the EC
since 2000 through a variety of funding mechanisms. To resolve the
issue of information dispersion, Orphanet provides direct online access
to an inventory and encyclopaedia of rare diseases. Orphanet attributes
a unique identiﬁer (Orphacodes, 3.3) to each disease and places them in
a polyhierarchial classiﬁcation of rare diseases. Orphanet provides ex-
pert validated information on expert services in its 37 partner countries
with the input of national partner teams. These services include expert
centres, clinical laboratories, research projects, registries, biobanks, and
patient organisations. An inventory of orphan drugs is also maintained.
Orphanet is available in 7 languages (English, French, Spanish, German,
Italian, Portuguese, and Dutch).
To support policy makers, Orphanet regularly publishes reports in a
collection entitled ‘Orphanet Report Series’, including lists of rare dis-
eases with their prevalence [30,31], lists of orphan drugs in Europe
[28], and lists of rare disease registries in Europe [22]. A number of
Orphanet datasets are also directly accessible in a number of re-usable
formats via Orphadata [32] in order to ensure the dissemination of the
Orphanet nomenclature (3.3) of rare diseases and maximise the use of
Orphanet's data for research and policy-making purposes.
3.7.2. Helplines
To provide information on rare diseases and services at national
level, rare disease speciﬁc helplines and centres providing information
on rare diseases have been established in some European countries,
often at the initiative of patient organisations. In some countries,support is provided to these services through national rare disease
plans/strategies.
3.7.3. OrphaNews
OrphaNews [5] is the bi-monthly e-newsletter of the rare disease
community, co-ﬁnanced by the EC. With over 15000 subscribed
readers, the newsletter is a key dissemination tool within the rare dis-
ease community. OrphaNews provides updates on the latest political,
regulatory, and scientiﬁc developments in the ﬁeld of rare diseases,
gathered from a systematic review of the literature and information
submitted by national contact points across Europe. The newsletter is
available in English, French and Italian.
3.7.4. Report on the State of the Art of Rare Diseases Activities in Europe
Since 2010, the publication of an annual report on the State of theArt
of Rare Disease Activities in Europe [29] has been supported by the EC.
This multivolume report provides information concerning the state of
the art of activities at both European andMember State levels, in partic-
ular the advances made to date in the implementation of the Council
Recommendation on an Action in the ﬁeld of rare diseases, notably
the elaboration and implementation of national plans/strategies for
rare diseases at national level. Elaboratedwith the input of stakeholders
at national level with the help of the members of the Expert Group on
Rare Diseases, the report provides a transversal view of the rare disease
ﬁeld and its evolution over the past few years.
4. Conclusions
Great strides forward have been made from 2000 onwards to im-
prove care for patients through the rare disease related policies imple-
mented at European and national levels. The Regulation on Orphan
Medicinal Products has led to the development and marketing of over
80 new therapies for rare diseases. The Council Recommendation on
an action in the ﬁeld of rare diseases has encouraged Member States
to put into place plans and/or strategies to structure their policies in
the ﬁeld of rare diseases and the majority of European countries have
now adopted a plan/strategy with the remaining countries in an ad-
vanced stage of elaboration of their policies. The provision of centres
of expertise for rare diseases, improved codiﬁcation for rare diseases
and rare disease patient registries are key measures of these plans.
The EC is supported by an Expert Group on Rare Diseases which pro-
vides key recommendations to the EC and European Member States to
ensure that the political approach at European and national levels is co-
hesive and based on established multi-stakeholder consensus. The Di-
rective on Cross-Border Healthcare is opening new possibilities for the
exchange of expertise in the ﬁeld of rare diseases through the creation
of European Reference Networks. Research into rare diseases is being
boosted by investments made by the EC in rare disease related projects
that promote European research collaborations. The International Rare
Disease Research Consortium has been launched to reach the ambitious
goal of developing 200 new therapies for rare diseases and establishing
means to diagnose most rare diseases by 2020. The availability of infor-
mation on rare diseases has been improved thanks to the Orphanet da-
tabase, which provides expert-validated, free, on-line information
concerning rare diseases and orphan medicinal products accessible to
all audiences. Finally, the implication of patient associations in all of
these various areas means that patients' voices are heard and that the
cited policies translate into improved care for patients. Much has been
achieved in the 15 years following the ﬁrst European policy in the
ﬁeld of rare diseases, above all the creation of a cohesive and dynamic
multi-stakeholder community; however many challenges remain to
be surmounted in a particularly tense economic climate. Despite these
economic difﬁculties, it is hoped that the European experience will
serve other world regions in developing their own approaches in the
ﬁeld of rare disease policies to improve care for patients.
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